Parkinson's disease: new antibody improves clinical outcome

Prasinezumab, a monoclonal antibody targeting alpha-synuclein aggregation, shows promise in slowing motor deterioration in rapidly progressing Parkinson's disease (PD), according to an exploratory analysis from the phase 2 PASADENA clinical trial.

While there are currently no disease-modifying treatments for PD, prasinezumab offers a potential breakthrough by specifically binding to aggregated alpha-synuclein, a key driver of PD pathology. In the trial, prasinezumab significantly reduced motor symptom worsening in patients with rapidly progressing disease at the one-year mark, compared to those on placebo.

This finding highlights the need for further research to confirm prasinezumab's efficacy in broader PD populations and those with slower disease progression.

Source: Nature